See every side of every news story
Published loading...Updated

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

Summary by Clinical Trials Arena
Sellas Life Sciences has reported the multicentre Phase IIa trial data of SLS009, in treating relapsed/refractory (r/r DLBCL).The post Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment appeared first on Clinical Trials Arena.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Clinical Trials Arena broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)